Amgen's TEZSPIRE Breakthrough May Be a Double-Edged Sword

The recent positive Phase 3 CROSSING trial results for TEZSPIRE in treating eosinophilic esophagitis (EoE) have significant implications for Amgen's immunology portfolio and investment narrative. The data shows that TEZSPIRE achieved meaningful improvements in key outcomes with a consistent safety profile.

This development highlights how Amgen is extending the use of its first-in-class antibody across multiple epithelial-driven diseases, potentially deepening its immunology portfolio. However, the company's future story also rests on the success of its specialty medicines, such as Repatha and olpasiran.

The most recent announcement alongside TEZSPIRE's EoE results is Repatha's VESALIUS CV mortality data, which showed a 20% reduction in all-cause mortality and a 25% reduction in major cardiac events in high-risk patients without prior heart attack or stroke. These data points focus attention on the mounting risk that drug pricing reforms and value-based care could cap Amgen's long-term profitability.